In 2024, the field of cancer therapeutics has witnessed remarkable progress in targeting Claudin 18.2 (CLDN18.2).

Johnson & Johnson was swept into a mounting legal crisis centered on allegations that its talc-based products caused cancer.

In April 2021, Swiss pharmaceutical giant Roche celebrated the approval of its novel anti-influenza drug, Baloxavir Marboxil, in China.

In July 2024, Roche filed a lawsuit in a California district court that thrust Stanford University professors Maximilian Diehn and Ash Alizadeh into the center of a major controversy.

The patent dispute between Swiss pharmaceutical giant Roche and American biotech heavyweight Biogen over Tocilizumab has emerged as a focal point in the global competition surrounding biosimilars.

In March 2025, South Korea’s Ministry of Food and Drug Safety (MFDS) approved a total of 6 new FDCs across multiple therapeutic areas.

In March 2025, the global pharmaceutical sector witnessed a surge of innovation where technology deeply integrates with clinical needs, spanning key areas.

In February 2025, the global pharmaceutical industry witnessed a series of milestone post-marketing collaboration deals.

Our analysis of February data reveals key trends in global clinical-stage biopharmaceutical financing.

In February 2025, the global biopharmaceutical industry remains active in clinical-stage drug financing and collaboration activities.

Our analysis of February data reveals key trends in global preclinical-stage biopharmaceutical financing.

As global healthcare continues to demand innovative therapies, February 2025 has emerged as a critical period witnessing the robust growth of the biopharmaceutical sector.